ABSTRACT
improves glucose metabolism. However the effectiveness of exercise therapy is limited because of poor compliance or disability level (6) .Brisk walking for 2 km or gardening work for 30 minute is sufficient, but patients with retinopathy should avoid isometric exercises and weight lifting (7) .
Oral hypoglycemic agents are often effective in patients with NIDDM after diet and exercise therapy have failed; Sulfonylurea drugs are not suitable for obese patients. They suffer from allergy and bone marrow depression. Some patients also suffer from gastrointestinal distress, anorexia lethargy, dizziness etc. (8) . Biguanides are suitable for obese diabetics and they are highly effective in lowering the blood sugar (9) . The former groups of drugs stimulate the pancrease for secretion of insulin while the latter group have no such action but they increase peripheral up take of glucose, impair its absorption from the bowel and decrease its output from the liver. Advantages of biguanides are that they are useful in middle aged obese diabetics and that they keep down the body weight (10) . However they have a disadvantage that they promote lactic acidosis. Biguanids like metformin potentiate insulin action also (9) and that in turn reduces fasting and postprandial hyperglycemia and glycosilated hemoglobin (Hb A 1c ). UK prospective study group report (10) shows that obese patients with metformin therapy alone had a 32 percent
INTRODUCTION
Diet restriction is the corner stone of all the therapeutic regimes for type II diabetes. Proper dietary choice along with exercise therapy is important for all patients with NIDDM. Unfortunately dietary habits are often difficult to change (1) without the help of a dietician who shall formulate a proper diet with choices of the patient (2) . Approximately 80% of the patients with NIDDM are overweight (3). Moderate weight loss, calorie restriction and exercise are beneficial for obese diabetic patients to control their blood sugar. In terms of calories 50 to 60 percent should be complex carbohydrates, 15 to 20% should be biologically rich proteins and 20 to 25 percent should be fat with a ratio of 2:1 for unsaturated to saturated fat (4) . Those with renal diseases may require a diet with less protein and those with carbohydrate induced hypertriglyceridemia may require more unsaturated fat and fewer carbohydrates (5) . Increased physical activity decreases insulin resistance and lower risk of developing any diabetes related complications e.g. macro and micro vascular complications. Side effects of metformin therapy include anorexia, diarrhoea, nausea and abdominal discomfort (11) . It is effective in non obese diabetics also (12) .
A class of oral drugs called thiazolidinediones sensitize insulin action and decrease hepatic gluconeogenesis. Some side effects reported for a member of this group viz; pioglitazone are headache, upper respiratory tract infection, sinusitis and myalgia (13) . Pioglitazone is peroxisome proliferators-activated receptor agonist that increases transcription of insulinresponsive genes and increases insulin sensitivity. Pioglitazone like other members of this group ameliorates insulin resistance associated with NIDDM without stimulating insulin release or hypoglycemia (14) . The mean serum half life of pioglitazone ranges from 3 to 7 hours (15). The major aim of the study was to show the beneficial effects of pioglitazone + metformin therapy, in obese diabetic patients. This was compared with the effects of diet control cum exercise and also that of monotherapy with metformin. For this the parameters measured are fasting blood sugar (FBS), Glycated Hemoglobin (HbA 1c ), Aspartate transminase (AST), Alanine transaminase (ALT) and J glutamyl transferase (GGT) and the general well being of the patients are also assessed.
MATERIALS AND METHODS
Forty five diabetic patients in the age range of 40-65 years and under the treatment of Dr.Varghese Chemmanum at S.H.Medical Centre, Kottayam have been diagnosed as NIDDM patients and they were selected for the present study. These patients gave the formal consent and participated in the study. They were classified into three groups containing 15 in each on the basis of the therapy they were asked to follow. Groups I & II were newly diagnosed patients and group III were under treatment for one year with sulfonylurea and metformin combination therapy which ultimately didn't control the diabetes. Standard doses of drugs were used.
Group I : Newly diagnosed 15 NIDDM patients were asked to follow diet control and exercise (8 males of age range 40-55 years and 7 females of 45-60 years) Group II : Newly diagnosed 15 NIDDM patients with obesity.
They were put on metformin therapy (9 males of age range 40-60 years and 6 females of 42-65 years) Group III : 15 NIDDM obese patients who were under combined therapy of sulfonylurea and metformin for one year and switched over to combination therapy of metformin and pioglitazone. (7 males of age range 50-65 years and 8 females of 45-65 years) Diets of all groups consisted of whole wheat, unpolished rice, potatoes peas, beans, skimmed milk, lean meat and fish as formulated by a dietician.
Obesity was determined based on minimum grade BMI values >25kg/m 2 .
The initial blood samples were collected from patients after an overnight fasting while they were admitted to the hospital for glycemic control. Blood was with drawn from the median cubital vein in the anticubital fossa or crook of the elbow is the preferred site. The puncher site was then cleaned with an antiseptic spirit and tourniquet was placed around the upper arm, i.e. 4 inches above the intended puncture site to obstruct the return of venous blood to heart and to distend the vein. A needle was inserted into the vein and blood was collected using a syringe. During the procedure, the tourniquet was removed and samples of blood were collected into clean labeled capped tubes for estimation of various parameters FBS (16), HbA 1c (17) , AST (18) , ALT (19) and GGT (20) .
For estimation of FBS blood was collected into tubes containing potassium oxalate and sodium fluoride in the ratio 2:1. The samples were centrifuged and plasma was collected for the estimation of glucose. For the estimation of HbA 1c , a haemolysate of the blood was prepared and the labile fraction was eliminated when Hbs were retained on a column of cationic exchange resin. HbA 1c is specifically retained on washing away other Hbs by two reagents viz; (1). 30 ml potassium biphosphate buffer, 50 mmol/L, pH 5.0 and (2) After hospital admission, doses of the drugs were adjusted so that a good glycemic control was achieved. After a week these patients were sent home with instructions to take medicines as the case may be and follow a life style and dietary habit befitting a diabetic patient i.e. eat only the initially formulated diet by the dietitian (4, 5) at home at definite time intervals and do moderate work or walk up to 2km daily if they can. A three month appointment was fixed for them and their blood was collected again after overnight fasting for measuring all the parameters as before. The results were analyzed according to the student's t test and the levels of significances were noted. Table I In diet control and exercise group1, the FBS level decreased very significantly by 24 % ( P<0.001). However in their enzyme levels viz. AST, ALT and Gamma glutamyl tranferase and Hb A 1c level there was no significant variation in a period of three months treatment. Gamma GT are non significantly elevated. Metformin is contraindicated in population who take alcohol and the fact that some of them were alcoholic might have caused a marginal elevation of those two enzymes in serum. The results showed that the metformin therapy is very effective for obese NIDDM patients.
RESULTS

Results are given in
The group III patients showed a marked amelioration of hyperglycemia with combination therapy of pioglitazone and Effects of diet cum exerclse or metformin with or without piolitazone in diabeties metformin. These patients previously failed to respond to a combination therapy of sulfonylurea and metformin. The tremendous improvement observed in their blood sugar control is mainly due to the insulin sensitizer pioglitazone. However this type of combined therapy adversely affected the serum enzymes AST, ALT and Gamma GT i.e. all three enzymes increased their levels in serum very significantly. Pioglitazone treatment showed previously also an adverse effect on serum transaminases and Gamma GT level (21). The highest fall of FBS(58%) observed in combined therapy may be due to two factors. i.e. due to very high pretreatment level of FBS and also due to insulin sensitizer action of pioglitazone. Similarly the comparatively higher FBS fall (45%) for metformin group over the diet control cum exercise group (24%) may be due to fact that the pretreatment level of FBS in the former group was about 37% higher than of the latter and that for the obese group metformin is the drug of choice that worked here also as it enhances the peripheral uptake of glucose. In the last two groups we can observe a parallel decrease of HbA 1c level along with FBS fall i.e. 33% in the metformin group and 50% in the combined therapy group. Therefore combination therapy is far more effective than monotherapy for controlling NIDDM, but the adverse effect of pioglitazone on the liver should also be taken into account and proper adjustment of its dose is warranted. In order to get a better control of diabetes mellitus combination therapy may be encouraged but dose adjustment with periodic monitoring of the level of the affected enzymes is very necessary to control the bad effects of the insulin sensitizer.
There are many other studies which support the beneficial effects of pioglitazone in combination with hypoglycemic agents or insulin. In an observational report trioglitazone, rosiglitazone and pioglitazone were compared in a limited number of patients; changes in HbA 1c were similar for the three agents, whereas the effects on lipoprotein metabolism were different. Pioglitazone reduced serum triglycerides and increased HDL-C to a greater extent than either trioglitazone or rosiglitazone. In addition, trioglitazone and rosiglitazone increased LDL-C whereas pioglitazone did not (22, 23) .Interestingly trioglitazone was shown to decrease the proportion of dense LDL in obese subjects despite its LDL-C raising effect (24) . In a recent study on NIDDM patients by Dorsa et al (25) ; the combination of glimepiride with pioglitazone (G+P) or rosiglitazone (G+R) significantly improved glycemic control in the study patients. This treatment also controlled plasma HbA 1c satisfactorily. However only G+P controlled the lipid profile particularly the lipoprotein variables. On the contrary combination therapy of G+R experienced a significant increase in most of the lipid risk factors for Coronary Vascular Disease (CVD). Overall no significant changes were observed with respect to plasma aminotransferase activities. Only three out of forty five patients, with G+P group and five out of forty five in G+R group experienced mild to moderate adverse effects, that did not cause withdrawal from the trial. In another study with pioglitazone in combination with insulin on NIDDM patients by Mattoo et al (26) they observed that only in those patients whose disease was inadequately controlled with insulin monotherapy, that pioglitazone + insulin combination therapy improved the glycemic control. All these studies and our present findings stress the importance of pioglitazone in combination therapy but with all the required precautions.
